| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
NDA Submission example | NDA | — | Subscribe to access the data. | Biologics | Dermatologic System | ||
NDA Submission example | NDA | — | Subscribe to access the data. | Biologics | Dermatologic System | ||
NDA Submission example | NDA | — | Subscribe to access the data. | Biologics | Dermatologic System |
Recent Updates
Recently added Catalysts
Ligand Pharmaceuticals Incorporated$297.55
+1.29 (+0.44%)
B 64Pipeline Score Undervalued Pharma · Commercial
Market Cap
4.60 B
EPS
7.84
P/E Ratio
31.09 $
Value Trade
36.61 M
SEC Financials
Q1 2026Dilution Risk
Revenue
51.72 M
R&D Expenses
2.15 M
Operating CF
48.69 M
Total Assets
1.53 B
Total Liabilities
534.78 M
Equity
997.32 M
D/E Ratio
12,345
5.85 %
Week
0.57 %
1 Month
23.36 %
3 Month
14.96 %
6 Month
83.83 %
5 Year
194.01 %
All Time
Cash Data
Cash Position
779.40 M
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
May 8, 2026
Overview
Volume
65.98 K
52 Week Range
98.89 - 247.38
% held by Insiders
2.47 %
% held by Institutions
105.61 %
Enterprise Value
4.27 B
Total Shares
20.04 M
Short %
10.85 %
Float Shares
18.88 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Ligand Pharmaceuticals Incorporated
425Total events
9Upcoming
223Tier-1 (high impact)
2015 – 2027Coverage
Upcoming catalysts 2
TBD
T2Enrollment Complete
Subscribe to view catalyst details
TBD
T2R&D Day
Subscribe to view catalyst details
Event history 2
TBD
▲AcquiredCorporate
Subscribe to view catalyst details
TBD
◆AcquisitionCorporate
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2024-09-05 | FILSPARI® (sparsentan) | PDUFA Date | PDUFA | Approved | – | – | – |
2024-09-05 | FILSPARI® (sparsentan) | PDUFA Date | PDUFA | Approved | – | – | – |
2024-09-05 | FILSPARI® (sparsentan) | PDUFA Date | PDUFA | Approved | – | – | – |
Drug Pipeline Intelligence
B64
Pipeline Score $4.6B
Pipeline ValueUndervalued
Valuation Signal25
Drugs Scored3.3x
rNPV / MCap Top 91%
Small Cap (rank 83 of 912)
Percentile RankLigand Pharmaceuticals Incorporated holds a solid B-grade pipeline (64/100), with $14.1B risk-adjusted pipeline value, led by LGD-6972 in Type 2 Diabetes Mellitus (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LGD-6972 Small molecule | Type 2 Diabetes Mellitus | Phase 2 | NCT02250222 | 23% | $4.7B | COMPLETED | 252 | - | - | Jun 1, 2015 | - | Jun 11, 2015 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
FILSPARI | focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome | Phase 3 | 2026-04-14 | 46% reduction in proteinuria from baseline to Week 108 compared to 30% for those treated with maximum labeled dose irbesartan (nominal p-value, 0.0299); 48% reduction in proteinuria from baseline to Week 108 compared to 27% for those treated with irbesartan (nominal p-value, 0.0075); treatment difference of 1.1 mL/min/1.73 m2 based on mean change from baseline to Week 108 Read More | Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI (sparsentan) in FSGS Read More | |
FILSPARI | focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome | Phase 3 | 2026-04-14 | 46% reduction in proteinuria from baseline to Week 108 compared to 30% for those treated with maximum labeled dose irbesartan (nominal p-value, 0.0299); 48% reduction in proteinuria from baseline to Week 108 compared to 27% for those treated with irbesartan (nominal p-value, 0.0075); treatment difference of 1.1 mL/min/1.73 m2 based on mean change from baseline to Week 108 Read More | Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI (sparsentan) in FSGS Read More | |
FILSPARI | focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome | Phase 3 | 2026-04-14 | 46% reduction in proteinuria from baseline to Week 108 compared to 30% for those treated with maximum labeled dose irbesartan (nominal p-value, 0.0299); 48% reduction in proteinuria from baseline to Week 108 compared to 27% for those treated with irbesartan (nominal p-value, 0.0075); treatment difference of 1.1 mL/min/1.73 m2 based on mean change from baseline to Week 108 Read More | Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI (sparsentan) in FSGS Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in LGND
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
LGND Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
LGND▲ +0.4%today
XOMA Royalty Announces Closing of Its Acquisition by Ligand
Ligand Pharmaceuticals has finalized its acquisition of XOMA Royalty Corporation, allowing XOMA stockholders to receive $39.00 in cash per share. Additionally, stockholders will receive a Contingent Value Right entitling them to a portion of potential proceeds from ongoing litigation. Following the acquisition, XOMA Royalty's shares will no longer be traded on the Nasdaq.
Read more →LGNDLigand Announces 2026 Investor Day in New York City
Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) has announced an Investor Day scheduled for December 8, 2026, in New York City. The event will feature presentations from senior management discussing the company's strategies, investment activities, and long-term financial projections. Ligand, known for its extensive royalty portfolio, aims to finance biopharmaceutical developments while ensuring steady revenue streams. Further details about the agenda and live webcast will be shared closer to the date of the event.
Read more →LGNDLigand to Participate in June Investor Conferences
Ligand Pharmaceuticals announced participation in two investor conferences scheduled for June 2026. The management team will hold one-on-one meetings at the Stifel 2026 Boston Cross Sector Conference on June 3 and will engage in a fireside chat at the Goldman Sachs Global Healthcare Conference on June 10. These events are positioned to enhance investor relations and showcase the company's innovative portfolio.
Read more →LGND▼ -9.6%on this news
Ligand Reports First Quarter 2026 Financial Results
Ligand Pharmaceuticals reported a 56% increase in royalty revenue for Q1 2026, driven by strong performance from Filspari and other assets. The company reaffirmed its full-year financial guidance, anticipating contributions from the pending acquisition of XOMA Royalty Corporation. Despite a GAAP net loss, adjusted net income showed a 30% growth compared to the previous year.
Read more →LGND▼ -9.6%on this newsshared move
Document Ligand Reports First Quarter 2026 Financial Results First quarter performance driven by strong year-over-year royalty revenue growth of 56% Reaffirms Previously Raised 2026 Full-Year Financial Guidance Reflectin
Ligand Pharmaceuticals reported impressive first quarter 2026 financial results, with a 56% increase in royalty revenue compared to the same period last year, amounting to $43 million. The company reaffirmed its full-year 2026 financial guidance and announced a definitive agreement to acquire XOMA Royalty Corporation, which is expected to close in the third quarter of 2026. This acquisition will significantly expand Ligand's royalty asset portfolio, adding over 120 new assets across various therapeutic areas. Additionally, Ligand celebrated the full FDA approval of Filspari for focal segmental glomerulosclerosis, strengthening its commercial offerings.
Read more →LGNDLigand to Participate in May 2026 Investor Conferences
Ligand Pharmaceuticals announced its participation in upcoming investor conferences, where its senior management will engage in one-on-one meetings with investors. The company is recognized for its extensive portfolio of biopharmaceutical royalties and its commitment to financing late-stage clinical development programs. Interested investors can arrange meetings through designated representatives.
Read more →LGNDLigand to Participate in May Investor Conferences
Ligand Pharmaceuticals has announced its participation in several upcoming investor conferences in May 2026, showcasing its senior management team. Notably, CEO Todd Davis and president Wes Kaupinen will engage in a fireside chat at the H.C. Wainwright Royalty Company Conference. The company aims to foster investor relationships through one-on-one meetings at various events, emphasizing its role as a major player in the biopharmaceutical royalty space and its diversified portfolio of assets.
Read more →LGNDLigand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand's Position as a Leading Biopharma Royalty Aggregator Transaction expands Ligand's royalty portfolio to more than 200 assets and
Ligand Pharmaceuticals has announced its acquisition of XOMA Royalty Corporation for $39.00 per share in cash, totaling approximately $739 million. This strategic move is expected to enhance Ligand's royalty portfolio to over 200 assets and adds seven new commercial products. The acquisition will also immediately accrete to Ligand's earnings per share, with a projected increase in their 2026 adjusted EPS guidance. The deal has been approved by both companies' Boards of Directors and is expected to close in the third quarter of 2026, subject to customary conditions.
Read more →LGNDLigand to Report First Quarter 2026 Financial Results on May 7, 2026
Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) has announced that it will report its first quarter 2026 financial results on May 7, 2026. The company plans to hold a conference call at 8:30 a.m. Eastern time on the same day to discuss these results and provide a business update. Ligand is recognized as a leading royalty aggregator with a significant portfolio of biopharmaceutical royalties, enabling them to align capital with clinical success.
Read more →LGND▲ +8.9%on this news
Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI (sparsentan) in FSGS
Travere Therapeutics has received full FDA approval for FILSPARI (sparsentan), the first and only treatment for focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome. This milestone could drive long-term royalty growth for Ligand Pharmaceuticals, entitled to a 9% royalty on FILSPARI's global sales. The approval is based on positive results from the Phase 3 DUPLEX Study, where FILSPARI exhibited a significant reduction in proteinuria compared to the conventional treatment. With an estimated 30,000 patients in the U.S. affected by this condition, FILSPARI presents a critical option for managing FSGS.
Read more →LGNDLigand Advances Strategic Growth with Expanded and Strengthened Business Development Team
Ligand Pharmaceuticals has announced the appointment of Peter Renehan and Lee Brown as Vice Presidents of Investments and Business Development. Both bring significant experience from leading firms and will focus on sourcing royalty financing opportunities. Additionally, Lauren Hay is transitioning to a more prominent role to optimize Ligand's portfolio assets. These strategic hires are expected to enhance Ligand's long-term value creation.
Read more →LGNDLigand to Participate in March Investor Conferences
Ligand Pharmaceuticals announced its participation in several upcoming investor conferences, including the Leerink Partners Global Healthcare Conference and the ROTH Conference. Management will engage in one-on-one meetings and presentations to discuss the company's strategies and advancements. This initiative reflects Ligand's commitment to investor relations and its growth in the biopharmaceutical sector.
Read more →LGNDLigand Reports Fourth Quarter and Full Year 2025 Financial Results
Ligand Pharmaceuticals reported robust financial results for Q4 and full year 2025, with total revenues reaching $268.1 million, a 60% increase from 2024. The company exceeded its adjusted earnings per share guidance by 30% in Q4, driven by a significant rise in royalty revenues. Ligand reaffirmed its financial guidance for 2026, expecting revenues between $245 million and $285 million.
Read more →LGNDDocument Ligand Reports Fourth Quarter and Full Year 2025 Financial Results Robust financial performance driven by full year 2025 royalty revenue growth of 48% Reiterating 2026 financial guidance of $245-$285 million in
Ligand Pharmaceuticals reported robust financial results for Q4 and full year 2025, with total revenues reaching $268.1 million, a significant increase from $167.1 million in 2024. The royalty revenue surged by 48%, mainly due to improved sales of several partnered products. The company reaffirmed its 2026 financial guidance, projecting total revenue between $245 million and $285 million. Despite this positive outlook, Ligand noted a financial royalty asset impairment related to returned programs.
Read more →LGNDLigand to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
Ligand Pharmaceuticals announced it will report its fourth quarter and full year 2025 financial results on February 26, 2026. A conference call will be held at 8:30 a.m. ET to discuss these results and provide a general business update. The company emphasizes its commitment to supporting clinical development through strategic partnerships and innovative technologies.
Read more →LGNDLigand to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Ligand Pharmaceuticals announced that CEO Todd Davis and CFO Tavo Espinoza will participate in a fireside chat at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026. The event will be held virtually, and Ligand management will also conduct one-on-one meetings with investors. The company aims to generate value through a diversified portfolio and strategic partnerships.
Read more →LGNDLigand Hosts 2025 Investor Day and Introduces 2026 Guidance
Ligand Pharmaceuticals held its Investor Day, revealing optimistic financial guidance for 2026, with projected revenues of $245 million to $285 million. The company anticipates a significant increase in royalty revenue, notably from launches and partnerships such as Zelsuvmi. Management emphasized the strong outlook driven by a $1 billion capital reserve aimed at future growth. Overall, the event highlighted Ligand’s strategic focus on financial performance and innovation in the biopharmaceutical landscape.
Read more →LGND▲ +9.4%on this news
Ligand Reports Third Quarter 2025 Financial Results and Raises Guidance
Ligand Pharmaceuticals reported a significant increase in its third-quarter 2025 financial results, with total revenues rising to $115.5 million, a 123% increase from the previous year. The company has raised its full-year revenue guidance to between $225 million and $235 million, reflecting strong growth in royalty revenues. Ligand's CEO highlighted successful strategic investments, including a merger with Channel Therapeutics, which contributed to shareholder value.
Read more →LGND▲ +9.4%on this newsshared move
Document Ligand Reports Third Quarter 2025 Financial Results and Raises Guidance Third quarter performance driven by strong portfolio royalty revenue growth of 47% 2025 full year revenue guidance increased to $225 millio
Ligand Pharmaceuticals has reported a 123% increase in total revenues for the third quarter of 2025, driven by strong royalty growth and a gain from the Pelthos sale. The company has raised its full-year revenue guidance to $225 million - $235 million and adjusted earnings per share expectations to $7.40 - $7.65. Management noted the successful financing activities and strategic investments that contributed to this positive growth trajectory. Additionally, Ligand's cash and investments now total $664.5 million, indicating strong financial health.
Read more →LGNDLigand to Participate in November Investor Conferences
Ligand Pharmaceuticals announced that CEO Todd Davis and CFO Tavo Espinoza will participate in upcoming investor conferences. They will host one-on-one meetings with investors, emphasizing the company's commitment to investor relations. Ligand aims to generate value through its diversified portfolio and innovative biopharmaceutical technologies.
Read more →LGNDLigand to Report Third Quarter 2025 Financial Results on November 6, 2025
Ligand Pharmaceuticals announced that it will report its financial results for the third quarter of 2025 on November 6, 2025. The company will also host a conference call at 8:30 AM ET to discuss these results and provide a business update. Ligand's business model focuses on partnering with pharmaceutical companies and generating revenue through licensing and financing high-value medicines. The company's diversified portfolio aims to offer investors valuable participation in the biotech sector.
Read more →LGNDLigand to Host Investor Day on December 9, 2025
Ligand Pharmaceuticals has announced its annual Investor Day scheduled for December 9, 2025, in New York City. The event will feature presentations from CEO Todd Davis and CFO Tavo Espinoza, focusing on the company's strategy and financial outlook. A guest speaker from Pelthos Therapeutics will discuss the launch of a new FDA-approved treatment for molluscum contagiosum. The event will also be available via live webcast.
Read more →LGNDLigand Partner SQ Innovation Receives FDA Approval for Lasix® ONYU, an At-Home Treatment for Edema in Heart Failure Patients
Ligand Pharmaceuticals announced that its partner SQ Innovation has received FDA approval for Lasix ONYU, a novel drug-device combination for treating edema in heart failure patients. This at-home treatment allows for subcutaneous administration, reducing the need for hospital visits. The product utilizes Captisol technology to enhance drug formulation and is expected to be available in late 2025.
Read more →LGNDLigand to Participate in September Investor Conferences
Ligand Pharmaceuticals announced its participation in two upcoming investor conferences: the Citi 20th Annual BioPharma Conference on September 3, 2025, and the H.C. Wainwright 27th Annual Global Investment Conference on September 9, 2025. The company's CEO Todd Davis and CFO Tavo Espinoza will be involved in discussions and presentations. In addition, Ligand management intends to host one-on-one meetings with interested investors, highlighting their commitment to investor relations.
Read more →LGNDLigand Announces Closing of Convertible Senior Notes Offering
Ligand Pharmaceuticals has completed its offering of $460 million in convertible senior notes due 2030. The net proceeds, approximately $445.1 million, will be used for general corporate purposes, including stock repurchases. The company also engaged in convertible note hedge transactions to mitigate potential dilution, although the associated warrant transactions could introduce some dilution risk.
Read more →LGNDLigand Announces Pricing of $400 Million Convertible Senior Notes Offering
Ligand Pharmaceuticals has announced the pricing of $400 million in convertible senior notes due 2030. The offering is aimed at qualified institutional buyers and is expected to close on August 14, 2025. Ligand plans to use the proceeds for various corporate purposes, including stock repurchases and financing convertible note hedge transactions. The notes will accrue interest at 0.75% per annum and have specific conditions for conversion.
Read more →LGNDLigand Announces Proposed Offering of $400 Million of Convertible Senior Notes Due 2030
Ligand Pharmaceuticals announced its intention to offer $400 million in convertible senior notes due 2030. The offering is a private placement aimed at qualified institutional buyers and may be expanded by an additional $60 million. Proceeds will be used for convertible note hedge transactions, share repurchases, and general corporate purposes. The company anticipates some market risk and potential dilution of its common stock as a result of the offering.
Read more →LGNDDocument Ligand Reports Second Quarter 2025 Financial Results and Raises Guidance Second quarter performance driven by strong portfolio royalty revenue growth of 57% 2025 full year revenue guidance increased to $200 mill
Ligand Pharmaceuticals reported strong financial results for the second quarter of 2025, showcasing a 57% increase in royalty revenue, which contributed to raising its full-year revenue guidance to between $200 million and $225 million. The company announced a core adjusted net income increase to $32 million for Q2 2025, up from $25.8 million year-over-year. Despite showing overall growth, Ligand recorded a GAAP net loss of $37.6 million for the first half of the year, stemming from previous financial impairments. The company is optimistic about future growth due to its commercial-stage portfolio and strategic partnerships.
Read more →LGNDLigand Reports Second Quarter 2025 Financial Results and Raises Guidance
Ligand Pharmaceuticals reported a strong financial performance for the second quarter of 2025, highlighting a 57% increase in royalty revenue. The company has raised its full-year revenue guidance from a previous $180 million–$200 million range to $200 million–$225 million. Additionally, adjusted earnings per diluted share are expected to be between $6.70 and $7.00, marking an optimistic outlook for investors. The success is attributed to key partnerships, including the commercial launch of Zelsuvmi and strategic acquisitions enhancing their portfolio.
Read more →LGNDLigand and Medtronic Commit $70 Million in Strategic Capital to Orchestra BioMed
Ligand Pharmaceuticals and Medtronic have committed a total of $70 million to Orchestra BioMed to support its late-stage cardiology programs. Ligand will invest $35 million and an additional $5 million through a private placement, while Medtronic will contribute $30 million, including a $10 million private placement. The investment is tied to the development of AVIM therapy and the potential for creating leadless pacemakers, aimed at improving treatments for patients with uncontrolled hypertension. This collaboration reflects confidence in the clinical progress of Orchestra BioMed's innovative therapies.
Read more →LGNDLigand to Report Second Quarter 2025 Financial Results on August 7, 2025
Ligand Pharmaceuticals has announced that it will report its second quarter 2025 financial results on August 7, 2025. A conference call will follow at 8:30 AM ET to discuss these results and provide a business update. The announcement underscores Ligand's commitment to transparency and investor relations. The company's strategy includes partnerships with major pharmaceutical firms to enhance revenue through royalties and technological licensing.
Read more →LGNDLigand Partner Pelthos Therapeutics Launches ZELSUVMI™
Ligand Pharmaceuticals announced the commercial launch of ZELSUVMI™ (berdazimer), the first FDA-approved topical gel for at-home treatment of molluscum contagiosum. The launch by its partner Pelthos Therapeutics will benefit millions, especially children, suffering from this viral skin condition. Ligand has also secured a $5 million milestone payment and is entitled to a 13% royalty on worldwide sales of the product. This milestone signifies the ongoing success and collaboration within Ligand's strategic business model.
Read more →LGNDLigand Announces Completion of Pelthos Therapeutics Merger with Channel Therapeutics
Ligand Pharmaceuticals has completed its merger with Channel Therapeutics, resulting in the formation of Pelthos Therapeutics, which will trade under the ticker 'PTHS' starting July 2, 2025. Concurrently, Ligand has invested $18 million in Pelthos, which aims to launch ZELSUVMI, a novel treatment for Molluscum contagiosum infections, in July 2025. The merger aims to leverage the combined strengths in drug development and innovation, while Pelthos will also explore the potential of existing pain management programs from Channel Therapeutics.
Read more →LGNDLigand Announces 2025 Investor Day in New York City
Ligand Pharmaceuticals has announced an Investor Day scheduled for December 9, 2025, in New York City. The event will feature presentations from the company's senior management, focusing on Ligand's strategy, investment activities, and financial outlook. A live webcast will also be available for interested stakeholders. This event aims to enhance investor understanding of Ligand's operations and future directives in the biopharmaceutical sector.
Read more →LGNDLigand to Ring the Nasdaq Opening Bell on May 19, 2025
Ligand Pharmaceuticals announced that it will ring The Nasdaq Opening Bell on May 19, 2025, to celebrate recent company milestones. CEO Todd Davis highlighted the company's transformation into a profitable organization focused on acquiring and generating royalties from a diverse portfolio of biopharmaceutical products. The live ceremony will be broadcasted, and Davis emphasized their ongoing commitment to building momentum and supporting partners in developing breakthrough medicines. The event marks a significant moment in Ligand's history, reflecting its achievements and future potential.
Read more →LGNDDocument Ligand Reports First Quarter 2025 Financial Results First quarter performance driven by strong portfolio royalty revenue growth of 44% Strengthened commercial portfolio and pipeline through strategic transaction
Ligand Pharmaceuticals has reported a strong performance for the first quarter of 2025, with revenue growth driven primarily by a 44% increase in royalty revenue. The company is reaffirming its full-year financial guidance and has completed strategic transactions to enhance its commercial portfolio. However, Ligand also reported a GAAP net loss compared to a profit in the same quarter last year, attributed in part to one-time expenses. Stakeholders can expect a conference call for further details on their earnings and future outlook.
Read more →LGNDLigand Reports First Quarter 2025 Financial Results
Ligand Pharmaceuticals reported robust financial results for Q1 2025, showing a 46% revenue increase attributed to royalty growth and Captisol sales. The company reaffirmed its full-year guidance, projecting revenues between $180 million and $200 million and adjusted earnings per diluted share ranging from $6.00 to $6.25. Ligand also executed strategic transactions to enhance its commercial portfolio, specifically regarding its new treatment, ZELSUVMI, which received FDA approval in 2024. Despite the positive growth, Ligand recorded a notable GAAP net loss and increased expenses in R&D and administrative areas.
Read more →LGNDLigand to Report First Quarter 2025 Financial Results on May 8, 2025
Ligand Pharmaceuticals is set to report its first quarter 2025 financial results on May 8, 2025, before the U.S. markets open. Following the report, the company will host a conference call to discuss the results and provide a general business update. This engagement with stakeholders underscores Ligand’s commitment to transparency and investor communication.
Read more →LGNDLigand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics
Ligand Pharmaceuticals' subsidiary Pelthos Therapeutics has announced a merger with Channel Therapeutics, combining resources to commercialize the FDA-approved ZELSUVMI, a novel treatment for Molluscum contagiosum. This transaction aims to raise $50 million in equity capital, positioning the newly formed company for expedited commercialization under the name Pelthos Therapeutics. The merger underscores a focus on addressing unmet medical needs in dermatology and incorporates existing pain treatment programs from Channel. Both companies' executives expressed strong optimism about the financial and strategic value this merger brings.
Read more →LGNDLigand Reports Fourth Quarter and Full Year 2024 Financial Results
Ligand Pharmaceuticals reported strong financial results for the fourth quarter and full year of 2024, highlighting a 28% growth in royalty revenue. Despite a GAAP net loss of $31.1 million for the fourth quarter, the company anticipates multiple value-driving milestones in 2025, including the launch of ZELSUVMI. The management reaffirmed its financial guidance for 2025, projecting total revenues between $180 million and $200 million. The increase in operational costs and impairment losses from discontinued programs, however, raised some concerns regarding financial stability.
Read more →LGNDDocument Ligand Reports Fourth Quarter and Full Year 2024 Financial Results Robust financial performance driven by full year 2024 royalty revenue growth of 28% Reiterating 2025 financial guidance of $180-$200 million in
Ligand Pharmaceuticals announced its financial results for Q4 and the full year of 2024, showcasing a substantial revenue increase driven by a 28% rise in royalty revenue. The company reiterated its financial guidance for 2025, projecting revenues between $180-$200 million. Additionally, significant progress was noted with FDA approvals for key portfolio products, positioning Ligand for future growth. However, the company reported a net loss in Q4 2024, indicating financial challenges despite revenue growth.
Read more →LGNDLigand Leads $75 Million Royalty Financing in Castle Creek Biosciences
Ligand Pharmaceuticals has completed a $75 million royalty financing agreement with Castle Creek Biosciences to fund the Phase 3 clinical trial of D-Fi, aimed at treating dystrophic epidermolysis bullosa (DEB). Ligand invested $50 million, while co-investors contributed $25 million for a high-single digit royalty on sales. D-Fi, which is an autologous gene-modified cell therapy, is anticipated to significantly impact patients suffering from DEB. Both companies expressed enthusiasm for this collaboration, which aligns with their commitment to addressing unmet medical needs in rare diseases.
Read more →LGNDDocument FOR IMMEDIATE RELEASE Ligand Leads $75 Million Royalty Financing in Castle Creek Biosciences Capital will fund Castle Creek's D-Fi Phase 3 clinical trial for patients with dystrophic epidermolysis bullosa throug
Ligand Pharmaceuticals has led a $75 million royalty financing agreement with Castle Creek Biosciences to support the Phase 3 clinical trial of D-Fi for dystrophic epidermolysis bullosa (DEB). Ligand invested $50 million while co-investors contributed $25 million, securing a high-single digit royalty on D-Fi's worldwide sales. D-Fi is an innovative gene-modified cell therapy aimed at addressing a significant unmet medical need for patients with DEB. With FDA designations including Orphan Drug and Fast Track, the therapy's development signifies a promising advance in treating this rare genetic skin disorder.
Read more →LGND▲ +11.1%on this news
Document Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance Third quarter performance driven by strong portfolio royalty revenue growth 2024 full year revenue guidance increased to $160 million
Ligand Pharmaceuticals reported strong financial results for Q3 2024, revealing a significant revenue rise driven by portfolio royalty growth. The company has raised its full-year revenue guidance to between $160 million and $165 million, surpassing previous estimates. Notably, Ligand announced the successful commercial launches of multiple products, including Ohtuvayre and FILSPARI, which are expected to be key revenue drivers. However, the company also recorded a GAAP net loss of $7.2 million for the quarter, primarily due to financial adjustments and increased administrative costs.
Read more →LGNDDocument Ligand Reports Second Quarter 2024 Financial Results Conference call at 4 30 p.m. Eastern Time today
Ligand Pharmaceuticals reported its financial results for the second quarter of 2024, revealing total revenues of $41.5 million, a notable increase from $26.4 million in the same quarter of 2023. The company added four new commercial-stage programs in the first half of the year, with several products gaining FDA approval. Despite a GAAP net loss of $51.9 million attributed to investment fluctuations, adjusted net income showed improvement. Ligand's royalty portfolio has expanded to include 12 major programs as it aims for long-term growth.
Read more →LGNDDocument FOR IMMEDIATE RELEASE Ligand to Acquire APEIRON Biologics AG for $100 Million Acquisition provides Ligand with the royalty rights to QARZIBA , a highly differentiated, commercial oncology drug marketed in 35 cou
Ligand Pharmaceuticals has announced the acquisition of APEIRON Biologics AG for $100 million, gaining royalty rights to the oncology drug QARZIBA. This acquisition is projected to positively impact Ligand's earnings per share, increasing its 2024 adjusted EPS guidance by 17%. The transaction reflects Ligand's strategy of acquiring high-value medicines and expanding its commercial stage portfolio. Closing of the acquisition is anticipated in July 2024, pending a shareholder objection period and other conditions.
Read more →LGNDDocument Ligand Reports First Quarter 2024 Financial Results Conference Call Begins at 4 30 p.m. Eastern Time Today
Ligand Pharmaceuticals reported its financial performance for the first quarter of 2024, revealing a significant net income increase, primarily due to gains from investments. The company reaffirmed its financial guidance for the year, projecting total revenues between $130 million and $142 million. Key highlights included a new royalty financing agreement with Agenus and multiple upcoming PDUFA dates for pipeline products, which are expected to drive future growth despite a decrease in total revenues compared to the previous year. The company remains optimistic about its diverse portfolio and upcoming commercialization of its innovative products.
Read more →LGND▲ +19.9%on this news
Document Ligand Reports Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast at 8 30 a.m. Eastern Time Today
Ligand Pharmaceuticals reported its financial results for Q4 and full year 2023, highlighting substantial improvements in revenue and net income. The company's transformation into a more efficient, high-margin business is underscored by a successful year in royalties and a promising product pipeline, including the recent FDA approval of ZELSUVMI. With a reaffirmed financial outlook for 2024, Ligand aims to maintain its growth trajectory through strategic initiatives and expansion efforts. The conference call held today provides further details and insights into these developments.
Read more →LGNDDocument Ligand Reports Third Quarter 2023 Financial Results Raising 2023 Guidance Investor and Analyst Day to be held on Tuesday December 12th in New York City Conference call begins at 4 30 p.m. Eastern Time today SAN
Ligand Pharmaceuticals has announced its financial results for Q3 2023, reporting total revenues of $32.9 million, which is an increase from the previous year excluding COVID-19 sales. The company has raised its revenue guidance for the full year to between $126 million and $129 million. Notably, net loss from continuing operations was $10.3 million for Q3 2023, contrasting with a profit in the same quarter last year, primarily due to decreased Captisol sales linked to COVID-19. Ligand plans to hold an Investor and Analyst Day on December 12, 2023, to discuss their long-term growth strategy.
Read more →LGNDDocument Ligand Reports Second Quarter 2023 Financial Results Conference Call Begins at 4 30 p.m. Eastern Time Today SAN DIEGO, Calif. (
Ligand Pharmaceuticals reported its financial results for Q2 2023, indicating a net income of $2.3 million, down from $12.6 million in Q2 2022. The company's cash reserves stand strong at $219 million, and it is debt-free following the paydown of convertible notes. Ligand has affirmed its revenue guidance for 2023, projecting total revenues between $124 million and $128 million. However, there has been a notable decline in revenues attributed to COVID-19 related sales, affecting overall income figures.
Read more →LGNDDocument Ligand Reports First Quarter 2023 Financial Results 2023 Financial Guidance Raised Conference Call Begins at 4 30 p.m. Eastern Time Today SAN DIEGO, Calif. (
Ligand Pharmaceuticals (NASDAQ: LGND) reported its financial results for Q1 2023, showing a revenue increase to $44 million compared to $36.5 million in Q1 2022. The company raised its 2023 guidance, predicting royalties of $78-$82 million and an EPS of $4.60-$4.75. Notably, despite the positive revenue growth and increased guidance, the company faced challenges as it did not report any Captisol sales related to COVID-19 and a recent study of sparsentan did not meet its primary goals. The call included discussions on various partnerships and ongoing strategic developments.
Read more →LGNDDocument Ligand Reports Fourth Quarter and Full Year 2022 Financial Results 2023 Financial Guidance Raised Conference Call Begins at 4 30 p.m. Eastern Time Today SAN DIEGO, Calif. (
Ligand Pharmaceuticals reported its fourth quarter and full year 2022 financial results, revealing a net loss for Q4 2022. Despite the increase in royalties and a raised financial outlook for 2023, the company experienced lower revenues compared to the previous year. Ligand's financial guidance suggests a focus on returning to revenue growth, although challenges remain due to fluctuating Captisol sales related to COVID-19. The management remains optimistic about future opportunities and revenue growth stemming from the recent business updates.
Read more →LGND(1) Amounts represent non-cash debt related costs that are calculated in accordance with the authoritative accounting guidance for convertible debt instruments that may be settled in cash. (2) Amounts represent the amort
Contacts Ligand Pharmaceuticals Incorporated LHA Investor Relations Simon Latimer Bruce Voss Email investors ligand.com Email bvoss lhai.com Phone (858) 550-7766 Phone (310) 691-7100 Twitter Ligand_LGND Ligand Reports Third Quarter 2022 Financial Results Increased 202
Read more →LGNDFor the six months ended
Unaudited Pro Forma Condensed Consolidated Financial Statements On November, 1, 2022 (the "Distribution Date"), Ligand Pharmaceuticals Incorporated ("Ligand," "Company," "we," "us," or "our") completed the separation (the "Separation") of its antibody discovery business and cert
Read more →LGNDLigand Announces Record Date and Details for Distribution for OmniAb Spin-Off EMERYVILLE, Calif. (
Ligand Announces Record Date and Details for Distribution for OmniAb EMERYVILLE, Calif. (October 3, 2022) Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that its board of directors has set October 26, 2022 as the record date (Record Date) for the dividend of
Read more →LGNDLigand Pharmaceuticals Incorporated LHA Investor Relations Simon Latimer Bruce Voss investors ligand.com bvoss lhai.com (858) 550-7766 (310) 691-7100 Twitter Ligand_LGND # # # 2
Ligand Pharmaceuticals Appoints Jason Haas to its Board of Directors EMERYVILLE (June 29, 2022) - Ligand Pharmaceuticals Incorporated (NASDAQ LGND) ("Ligand" or "the Company") announces the appointment of Jason Haas to the Company's Board of Directors. Mr. Haas brings more than
Read more →LGNDAnalyst Teach - In
Analyst Teach - In June 21, 2022 11 am EDT 2 LEGAL DISCLAIMERS About this Presentation This presentation is for informational purposes only to assist interested parties in making their own evaluation with respect to a proposed business combination (the Business Combination) betw
Read more →LGNDLigand to Spin-Off its OmniAb Business Through Merger with Avista Public Acquisition Corp. II Transaction will result in OmniAb becoming an independent publicly traded company Ligand s shareholders to receive 100% of Lig
Ligand to Spin-Off its OmniAb Business Through Merger with Avista Public Acquisition Corp. II Transaction will result in OmniAb becoming an independent publicly traded company Ligand s shareholders to receive 100% of Ligand s shares in OmniAb through a tax-free distribution i
Read more →LGND▼ -8.4%on this news· ran to -22% by day 3
Document Ligand Reports Fourth Quarter and Full Year 2021 Financial Results Conference Call Begins at 4 30 p.m. Eastern Time Today EMERYVILLE, Calif. (
Ligand Reports Fourth Quarter and Full Year 2021 Financial Results Conference Call Begins at 4 30 p.m. Eastern Time Today EMERYVILLE, Calif. (February 17, 2022) - Ligand Pharmaceuticals Incorporated (NASDAQ LGND) today reported financial results for the three and 12 months ende
Read more →LGNDDocument Ligand Pharmaceuticals Appoints Dr. Jennifer Cochran to its Board of Directors EMERYVILLE (
Ligand Pharmaceuticals Appoints Dr. Jennifer Cochran to its Board of Directors EMERYVILLE (July 14, 2021) - Ligand Pharmaceuticals Incorporated (NASDAQ LGND) ("Ligand" or "the Company") announces the appointment of Jennifer Cochran, Ph.D. to the Company's Board of Directors, eff
Read more →LGND(1) Amounts represent non-cash debt related costs that are calculated in accordance with the authoritative accounting guidance for convertible debt instruments that may be settled in cash. (2) For the three months ended
Contacts LHA Investor Relations Bruce Voss Email bvoss lhai.com Phone (310) 691-7100 Twitter Ligand_LGND Ligand Reports First Quarter 2021 Financial Results Conference Call Begins at 4 30 p.m. Eastern Time Today SAN DIEGO (May 3, 2021) - Ligand Pharmaceuticals
Read more →LGNDDocument Ligand Reports Fourth Quarter and Full Year 2020 Financial Results Raises 2021 Financial Guidance Conference Call Begins at 8 30 a.m. Eastern Time Today SAN DIEGO (
Ligand Reports Fourth Quarter and Full Year 2020 Financial Results Raises 2021 Financial Guidance Conference Call Begins at 8 30 a.m. Eastern Time Today SAN DIEGO (February 3, 2021) - Ligand Pharmaceuticals Incorporated (NASDAQ LGND) today reported financial results for the th
Read more →LGNDDocument Ligand and GSK Enter Global Collaboration and License Agreement Leveraging Icagen's Discovery Technology to Target Neurological Disorders Ligand Group is eligible to receive an upfront payment of $7 million and
Ligand and GSK Enter Global Collaboration and License Agreement Leveraging Icagen's Discovery Technology to Target Neurological Disorders Ligand Group is eligible to receive an upfront payment of $7 million and potential milestone payments and fees of up to $154.5 million and ti
Read more →LGNDLigand to Divest Vernalis Research Operations Consideration includes $25 million cash payment plus Ligand retains economics on completed partnerships and share of economics on current collaborations SAN DIEGO, Calif. (
Ligand to Divest Vernalis Research Operations Consideration includes $25 million cash payment plus Ligand retains economics on completed partnerships and share of economics on current collaborations SAN DIEGO, Calif. (October 12, 2020) - Ligand Pharmaceuticals Incorporated (NA
Read more →LGNDCONTINGENT VALUE RIGHTS AGREEMENT This CONTINGENT VALUE RIGHTS AGREEMENT (this Agreement ), dated
CONTINGENT VALUE RIGHTS AGREEMENT This CONTINGENT VALUE RIGHTS AGREEMENT (this Agreement ), dated September 30, 2020, is by and between Ligand Pharmaceuticals Incorporated, a Delaware corporation ( Parent ) and American Stock Transfer & Trust Company, LLC, a New York limited li
Read more →LGNDTENDER AND SUPPORT AGREEMENT This TENDER AND SUPPORT AGREEMENT (this Agreement ) is entered into as of
TENDER AND SUPPORT AGREEMENT This TENDER AND SUPPORT AGREEMENT (this Agreement ) is entered into as of August 10, 2020, by and among Ligand Pharmaceuticals Incorporated, a Delaware corporation ( Parent ), Pelican Acquisition Sub, Inc., a Delaware corporation and wholly owned su
Read more →LGNDDocument Contacts Ligand Pharmaceuticals Incorporated LHA Investor Relations Patrick O'Brien Bruce Voss Email investors ligand.com Email bvoss lhai.com Phone (858) 550-7893 Phone (310) 691-7100 Twitter Ligand_LGND Ligand
Contacts Ligand Pharmaceuticals Incorporated LHA Investor Relations Patrick O'Brien Bruce Voss Email investors ligand.com Email bvoss lhai.com Phone (858) 550-7893 Phone (310) 691-7100 Twitter Ligand_LGND Ligand Completes Acquisition of Icagen Core Assets, Partnered Programs
Read more →LGNDLigand Appoints Pharmaceutical Executive Sarah Boyce to its Board of Directors
Contacts: Ligand Pharmaceuticals Incorporated LHA Todd Pettingill Bruce Voss investors@ligand.com bvoss@lhai.com (858) 550-7893 (310) 691-7100 @Ligand_LGND Ligand Appoints Pharmaceutical Executive Sarah Boyce to its Board of Directors SAN DIEGO (October 15, 2019) - Ligand Pha
Read more →LGNDInvestor Conference Call
Safe Harbor Statement The following presentation contains forward-looking statements by Ligand that involve risks and uncertainties and reflect Ligand's judgment as of the date of this presentation. Words such as "plan," "believe," "expect," "anticipate," "project," "intend," and
Read more →LGNDLigand Reports Second Quarter 2018 Financial Results
Contacts: Ligand Pharmaceuticals Incorporated LHA Investor Relations Todd Pettingill Bruce Voss Email: investors@ligand.com Email: bvoss@lhai.com Phone: (858) 550-7500 Phone: (310) 691-7100 Twitter: @Ligand_LGND Ligand Reports Second Quarter 2018 Financial Results Upd
Read more →LGNDLigand Reports First Quarter 2018 Financial Results
Contacts: Ligand Pharmaceuticals Incorporated LHA Investor Relations Todd Pettingill Bruce Voss Email: investors@ligand.com Email: bvoss@lhai.com Phone: (858) 550-7500 Phone: (310) 691-7100 Twitter: @Ligand_LGND Ligand Reports First Quarter 2018 Financial Results Conf
Read more →LGNDLigand Reports Third Quarter 2017 Financial Results
Contacts: Ligand Pharmaceuticals Incorporated LHA Investor Relations Todd Pettingill Bruce Voss Email: investors@ligand.com Email: bvoss@lhai.com Phone: (858) 550-7500 Phone: (310) 691-7100 Twitter: @Ligand_LGND Ligand Reports Third Quarter 2017 Financial Results SAN
Read more →LGNDforward-looking statements.
LIGAND PHARMACEUTICALS INCORPORATED ADJUSTED FINANCIAL MEASURES (Unaudited, in thousands) Three months ended September 30, Nine months ended September 30, 2016 2015 2016 2015 Net income $ 1,051 $ 199,165 $ 1,490 $ 223,483 Non-cash stock-based compensation expense
Read more →LGNDLigand Reports Third Quarter 2016 Financial Results
Contacts: Ligand Pharmaceuticals Incorporated LHA Todd Pettingill Bruce Voss investors@ligand.com bvoss@lhai.com (858) 550-7500 (310) 691-7100 Twitter: @Ligand_LGND Ligand Reports Third Quarter 2016 Financial Results Conference Call Begins at 4:30 p.m. Eastern Time Today SAN
Read more →LGNDLigand Announces Multi-program LTP Technology Licensing Agreement
Ligand Announces Multi-program LTP Technology Licensing Agreement with Nucorion Pharmaceuticals Newly-formed Nucorion, co-founded by Ligand, to pursue a pipeline of LTP-based programs for China and other markets SAN DIEGO (July 29, 2016) - Ligand Pharmaceuticals Incorporated
Read more →LGNDCERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION
CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. THIS LICENSE AGREEMENT (this Agreement ) is made this 19
Read more →LGNDLigand Pharmaceuticals Incorporated LHA Todd Pettingill Bruce Voss investors@ligand.com bvoss@lhai.com (858) 550-7500 (310) 691-7100 Ligand Summarizes the Accounting Impact of the Viking Therapeutics, Inc. IPO
Ligand Pharmaceuticals Incorporated LHA Todd Pettingill Bruce Voss investors@ligand.com bvoss@lhai.com (858) 550-7500 (310) 691-7100 Ligand Summarizes the Accounting Impact of the Viking Therapeutics, Inc. IPO and Updates 2015 Financial Guidance SAN DIEGO (June 2,
Read more →LGNDLigand and Pharmacopeia to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
PRINCETON, N.J., Nov. 4, 2008 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq:LGND) and Pharmacopeia (Nasdaq:PCOP), an innovator in the discovery and development of novel small molecule therapeutics, today announced that Dr. Joseph A. Mollica, Interim President an
Read more →LGNDLigand and Pharmacopeia to Present At the Oppenheimer 19th Annual Healthcare Conference
PRINCETON, N.J., Oct. 28, 2008 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq:LGND) and Pharmacopeia (Nasdaq:PCOP), an innovator in the discovery and development of novel small molecule therapeutics, today announced that John L. Higgins, President and Chief Execu
Read more →LGNDLigand to Acquire Pharmacopeia for Stock and Contingent Value Rights
Acquisition Would Result in Well Capitalized Company With Robust Royalty Assets and Broad Research Pipeline Conference Call Today at 5:30p.m. Eastern SAN DIEGO, Sept. 24, 2008 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq:LGND) announced today that it has ent
Read more →LGNDLigand Pharmaceuticals Incorporated (LGND) President and Chief Executive Officer to Ring the NASDAQ Stock Market Opening Bell
ADVISORY, Sept. 25, 2007 (PRIME NEWSWIRE) -- John L. Higgins, President and CEO of Ligand Pharmaceuticals Incorporated (LGND), along with the executive management team and Board of Directors, will preside over the opening bell. NASDAQ MarketSite - 4 Times Square - 43rd & Broa
Read more →Competitive Position
How LGND ranks across every disease it competes inCompetitive Position is a premium feature
See how LGND ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial